Why LENZ Therapeutics, Inc.’s (LENZ) Stock Is Down 7.33%
As of Tuesday, November 17, LENZ Therapeutics, Inc.’s LENZ share price has dipped by 7.33%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Tudor Pop
Tudor Pop
Rosalio Madrigal
| Share Statistics | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $120.0 | $433.9 | 24% |
|
| Shares Out (Mil) | 31.4 | 46.5 | 37% |
|
| Institutional Ownership | 96.1% | 82.2% | 69% |
|
| Float (Mil) | 22.2 | 47.7 | 30% |
|
| Beta | 1.81 | 0.74 | 89% |
|
| Avg Daily Volume (000s) | 995 | 345 | 68% |
|
| Price Change (52-week) |
(85.6%) | 52.0% | 7% |
|
| Growth | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | (1.6%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.753) | ($4.164) | ($1.205) | |
| Month Ago EPS | ($0.906) | ($4.203) | ($2.912) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.928) | ($4.245) | ($3.075) | |
| Year/Year Chg | (23.6%) | 46.1% | (83.6%) | |
| Financials | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $12 | $289 | 10% |
|
| Net Income (TTM) (Mil) | ($140) | ($11) | 9% |
|
| EPS (TTM) | ($4.480) | ($0.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($128) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $1 | 55% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($102) | $331 | 1% |
|
| Valuation | LENZ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.63 | 2.05 | 15% |
|
| P/E | na | 24.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 82.0% | 69.5% | 90% |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (66.7%) | (23.3%) | 9% |
|
| ROE | (72.7%) | (21.8%) | 12% |
|
| Liabilities to Assets | 8.5% | 31.2% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
LENZ Therapeutics, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors